---
title: "Obefazimod (ABX464) in Ulcerative colitis: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Humanistic burden and health-related quality of life. Topics: EQ-5D utilities, SIBDQ scores, and disease activity in 289 US and 1037 European adults with moderate-to-severe ulcerative colitis; Disease control, flares, and emotional impact in the UC Narrative global survey of 2100 patients; Bowel urgency and fecal urge incontinence in 200 US and 556 European patients with moderate-to-severe ulcerative colitis (CONFIDE); Anxiety and depression symptoms in 30 118 adults with inflammatory bowel disease: meta-analysis of 77 studies; 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### EQ-5D utilities, SIBDQ scores, and disease activity in 289 US and 1037 European adults with moderate-to-severe ulcerative colitis

> “N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared with active disease within each region).”
> “Similarly, patients with active disease also reported lower EQ-5D VAS and SIBDQ scores (adjusted means = 70.8 and 4.6, respectively) compared with patients in remission (adjusted means = 82.4 and 5.5) and deep remission (adjusted means = 88.6 and 5.9) (all P < 0.05).”
> “Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities.”

Source: [Armuzzi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6975026/)

<a id="topic-2.2.1.8.1-2"></a>

### Disease control, flares, and emotional impact in the UC Narrative global survey of 2100 patients

> “Surveys of patients with UC (self-reported diagnosis; n = 2100) and physicians (n = 1254) were completed across 10 countries by The Harris Poll between August 2017 and February 2018.”
> “The majority of patients (82%) had moderate to severe UC (based on medication history; those who had only ever taken 5-aminosalicylates were excluded); 67% described their UC as controlled with few to no symptoms. On average, patients experienced 4.3 flares (standard deviation, 7.4) in the past year.”
> “Globally, the majority of patients with moderate to severe disease (84%) reported UC to be mentally exhausting; even patients with milder UC (75%) or patients who self-reported being in remission (82%) agreed. Most patients (65%) felt that UC controlled their life rather than them controlling their UC”
> “Patients reported visiting the bathroom (for any reason, including to pass stool, air, blood, or mucus) a mean of 3.5 times (SD, 2.9) on their best day and 9.8 times (SD, 7.4) on their worst day.”
> “In total, 21% and 15% of patients self-reported receiving a diagnosis of anxiety or depression, respectively, although this finding varied by country.”

Source: [Dubinsky et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8528151/)

<a id="topic-2.2.1.8.1-3"></a>

### Bowel urgency and fecal urge incontinence in 200 US and 556 European patients with moderate-to-severe ulcerative colitis (CONFIDE)

> “Surveys were completed by 200 US and 556 European patients and 200 US and 503 European HCPs. The most common UC symptoms experienced in the preceding month were diarrhea, bowel urgency, and increased stool frequency. Many patients (45.0% of US patients, 37.0% of European patients) reported wearing diapers/pads/protection at least once a week in the past 3 months due to fear/anticipation of fecal urge incontinence. The top reasons for declining participation in social events, work/school, and sports/exercise were due to bowel urgency and fear of fecal urge incontinence.”
> “Over 30% of US patients and 40% of European patients do not feel comfortable discussing bowel urgency with their HCP (Figure 3C). The most common reason was due to feeling embarrassed to do so”

Source: [Travis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11144997/)

<a id="topic-2.2.1.8.1-4"></a>

### Anxiety and depression symptoms in 30 118 adults with inflammatory bowel disease: meta-analysis of 77 studies

> “Of 5544 studies identified, 77 fulfilled the eligibility criteria, including 30 118 patients in total. Overall, pooled prevalence of anxiety symptoms was 32·1% (95% CI 28·3-36·0) in 58 studies (I2=96·9%) and pooled prevalence of depression symptoms was 25·2% (22·0-28·5) in 75 studies (I2=97·6%).”
> “In studies that reported prevalence of anxiety or depression in patients with Crohn's disease and ulcerative colitis within the same study population, patients with Crohn's disease had higher odds of anxiety symptoms (OR 1·2, 95% CI 1·1-1·4) and depression symptoms (1·2, 1·1-1·4) than patients with ulcerative colitis.”
> “The prevalence of symptoms of anxiety (57·6% [95% CI 38·6-75·4]) or depression (38·9% [26·2-52·3]) was higher in patients with active IBD than in patients with inactive disease (38·1% [30·9-45·7] for anxiety symptoms and 24·2% [14·7-35·3] for depression symptoms; ORs 2·5 [95% CI 1·5-4·1] for anxiety and 3·1 [1·9-4·9] for depression).”

Source: [Barberio et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33721557/)

<a id="topic-2.2.1.8.1-5"></a>

### Health-related quality of life with approved advanced therapies: network meta-analysis of 28 randomized controlled trials

> “Twenty-eight RCTs were included; 26 reported HRQoL outcomes during induction and 15 during maintenance. During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30 mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated.”
> “SF-36 improvements were modest overall, with upadacitinib and vedolizumab showing selective advantages, while WPAI-UC benefits were observed with upadacitinib, vedolizumab, and ustekinumab.”

Source: [Katsoula et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/41284688/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
